Clinical study on the application of triple viable Bifidobacterium preparation in the treatment of diarrhea-predominant irritable bowel syndrome
腹泻型肠易激综合征应用双歧杆菌三联活菌治疗的临床研究

摘要

目的 探讨双歧杆菌三联活菌在腹泻型肠易激综合征（IBS-D）中的应用效果。方法 选取2021年5月至2025年5月IBS-D患者80例，随机分为对照组和观察组，各40例。对照组给予常规对症治疗，观察组加用双歧杆菌三联活菌。比较两组治疗前后腹泻次数、腹痛评分、生活质量及复发率。结果 观察组腹泻频率、腹痛评分改善明显优于对照组，生活质量评分显著提高，复发率降低，差异有统计学意义（P<0.05）。结论 双歧杆菌三联活菌可有效缓解IBS-D症状，提高生活质量，降低复发率，具有较高临床应用价值。

Abstract

Objective To explore the clinical efficacy of a triple viable Bifidobacterium preparation in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).
Methods A total of 80 IBS-D patients admitted from May 2021 to May 2025 were randomly assigned to a control group (n=40) and an observation group (n=40). The control group received conventional symptomatic treatment, while the observation group was additionally given the triple viable Bifidobacterium preparation. Stool frequency, abdominal pain scores, quality of life, and recurrence rates were compared before and after treatment.
Results The observation group showed significantly greater improvements in stool frequency and abdominal pain scores, higher quality of life scores, and lower recurrence rates compared with the control group (P<0.05).
Conclusion   The triple viable Bifidobacterium preparation can effectively relieve IBS-D symptoms, improve quality of life, and reduce recurrence, demonstrating high clinical application value.